BRISTOL-MYERS Squibb's (BMS) Sotyktu (deucravacitinib) is now listed on the PBS for adult patients living with severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Sotyktu's reimbursement is based on the outcomes of two pivotal, Phase three clinical trials (POETYK PSO-1 and POETYK PSO-2), which demonstrated superior efficacy of once-daily medication compared to placebo, and twice-daily apremilast, in 1,684 patients aged 18 years and older living with severe chronic plaque psoriasis.
"Today's reimbursement of Sotyktu is a positive step toward improving affordable treatment access for Australians living with this disease," according to BMS ANZ Medical Director, Dr Melinda Munns.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Oct 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Oct 23
